Home / Market News / $ADUS

$ADUS news and market catalysts

The 12 most recent market catalysts affecting $ADUS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

12 catalysts 0 high impact 8 bullish 1 bearish Healthcare Services
Nov 16, 2026 Corporate Catalyst Bullish Impact 55
RBC Lifts Price Target on Addus HomeCare to $141 From $134
RBC Capital Markets has raised its price target for Addus HomeCare (ADUS) from $134 to $141, while reiterating an 'Outperform' rating. This analyst upgrade signals increased confid…
Nov 12, 2026 Corporate Catalyst Neutral Impact 65
Addus HomeCare Officer Executes $12.2 Million Stock Sale
An officer at Addus HomeCare Corporation executed a significant sale of 99,000 shares, valued at approximately $12.2 million. This transaction is noteworthy because large insider s…
Nov 10, 2026 Corporate Catalyst Neutral Impact 65
Addus HomeCare Insider Sells Shares Worth $12,198,991
An insider at Addus HomeCare Corporation (ADUS) sold over $12 million worth of company stock, a substantial transaction reported via an SEC filing. This event is significant becaus…
Nov 5, 2026 Corporate Catalyst Bullish Impact 65
TD Cowen Raises Price Target on Addus HomeCare to $145
TD Cowen has raised its price target for Addus HomeCare (ADUS) to $145, up from $131, and reiterated its 'Buy' rating. This analyst action signals increased confidence in ADUS's va…
Nov 5, 2026 Corporate Catalyst Bullish Impact 65
UBS Raises Price Target on Addus HomeCare to $160
UBS has raised its price target on Addus HomeCare (ADUS) to $160 from $145, maintaining its 'Buy' rating. This upgrade is a direct result of the firm's updated assessment following…
Nov 5, 2026 Corporate Catalyst Bullish Impact 55
Truist Raises Price Target on Addus HomeCare to $148 From $135, Keeps Buy Rating
Truist Financial has raised its price target for Addus HomeCare (ADUS) from $135 to $148 and maintained its 'Buy' rating. This upgrade comes after the company's third-quarter 2026 …
Nov 4, 2026 Corporate Catalyst Bullish Impact 55
Barclays Adjusts Price Target for Addus HomeCare
Barclays updated its outlook on Addus HomeCare, raising its price target to $101 from $96. Despite this increase, the firm maintained its 'Underweight' rating, which is a key signa…
Nov 4, 2026 Corporate Catalyst Bullish Impact 55
BofA Securities Raises Price Target on Addus HomeCare
BofA Securities raised its price target for Addus HomeCare (ADUS) to $131 from $125 following the company's third-quarter financial report. This analyst action indicates a positive…
Nov 4, 2026 Corporate Catalyst Bullish Impact 55
Addus HomeCare Corporation Analyst Price Target Increased
Analysts have slightly raised their average 12-month price target for Addus HomeCare Corporation (ADUS) from $134.08 to $134.92. This modest increase, coupled with a maintained 'Bu…
Sep 14, 2026 Corporate Catalyst Bearish Impact 65
B of A Securities Downgrades Addus HomeCare to Neutral, Lowers Price Target to $125
B of A Securities analyst Joanna Gajuk downgraded Addus HomeCare (ADUS) from a 'Buy' rating to 'Neutral' and simultaneously lowered the price target from $140 to $125. This action …
Aug 10, 2026 Corporate Catalyst Neutral Impact 75
Addus HomeCare Announces That Heather Dixon, President And Chief Operating Officer, Is No Longer With The Company; Brad Bickham, Former President And COO At Addus, Has Agreed To Return As COO On An Interim Basis, Effective Immediately
Addus HomeCare announced a significant leadership change with the departure of Heather Dixon, President and Chief Operating Officer. This is a notable event as the COO role is crit…
Aug 5, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on Addus HomeCare, Raises Price Target to $134
RBC Capital's analyst Ben Hendrix maintained an 'Outperform' rating on Addus HomeCare (ADUS) and raised the price target from $130 to $134. This action signals continued confidence…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.